Pascal Schweizer

Aphton Corp. operates as a biopharmaceutical company, which is focused on the development and commercialization of pharmaceutical products for the treatment of cancer and gastrointestinal disease. The company was founded on May 12, 1981 and is headquartered in Philadelphia, PA.

Axys Pharmaceuticals, Inc. engages in the development of integrated drugs. The company is headquartered in South San Francisco, CA.

Lux Biosciences, Inc. provides therapies for treatment of ophthalmic diseases. It develops and commercializes medications for ophthalmic diseases. The company was founded by Ulrich M. Grau, Eddy Anglade, Clarke A. Atwell and Sidney L. Weiss in 2006 and is headquartered in Jersey City, NJ.

Anchor Therapeutics, Inc. designs and develops peptide modulators of G protein-coupled receptors (GPCRs). The firm engages in developing and licensing pepducin technology as a research tool for drug development; and pepducin drug candidates and novel molecules that are intended for targeting GPCR to allosterically modulate GPCR signaling. Its pepducin lipopeptides are designed to allosterically modulate internal cell signaling via specific interactions with intracellular GPCR domains. The company also focuses on developing its pepducin technology for creating new treatment options for regenerative medicine, diabetes, inflammation, and cancer. Anchor Therapeutics was founded by Thomas J. McMurry and Athan Kuliopulos in 2006 and is headquartered in Cambridge, MA.

TVM Capital GmbH (TVMC) is an international venture capital firm headquartered in Munich, Germany. Founded in 1983, the firm was formerly known as Techno Venture Management.

Founded in 1994, Hoechst Marion Roussel Ltd. (United Kingdom) is a British pharmaceutical company that manufactures pharmaceutical products. Part of Sanofi, the company is based in Guildford, UK.

igeneon Krebs-Immuntherapie Forschungs & Entwicklungs GmbH develops biological products to treat cancer and other diseases. It focuses on cancer immunotherapies designed to prevent or delay the formation of metastases in cancer of epithelial origin, including colorectal, breast and lung cancer. Founded in 1999, the company is headquartered in Vienna, Austria.

Shire Orphan Therapies GmbH engages in the development, manufacture, and distribution of chemical and biochemical products, ingredients, as well as pharmaceutical and diagnostic products. The company was founded in 1994 and is headquartered in Berlin, Germany.

Cardion GmbH develops biopharmaceutical products. It integrates synergistic local gene delivery stem cell engineering and tolerance induction capabilities to build cardiovascular gene therapy products. The company is headquartered in Dusseldorf, Germany.

Part of Abbott Laboratories, BASF Pharma Ltd. is a British company that produces excipients and active ingredients. The company is based in Kent, UK. The company was founded by Erich Schlick. BASF Pharma was acquired by Abbott Laboratories from BASF SE on March 02, 2001 for $6,128.79 million.

Part of Valerio Therapeutics SA, G2M Cancer Drugs AG is a German company that researches new anti-cancer therapeutics and develops selected late-stage products. The company is based in Frankfurt am Main, Germany. G2M Cancer Drugs was acquired by Topotarget A/S on March 01, 2005.

Affectis Pharmaceuticals AG discovers and develops drugs for the treatment of neurodegenerative and neuroinflammatory diseases. Its products in pipeline include AFC-5128, P2X7 Compounds, AFC-5278 and AFC-08. The company was founded in January 2004 by Florian Holsboer, Wolfgang Wurst and Herbert Stadler and is headquartered in Dortmund, Germany.

Amgen Rockville, Inc. develops and commercializes antibody-based products. Its product development pipeline includes novel antibodies generated with its BiTE antibody platform, as well as conventional monoclonal antibodies. The company was founded in 1993 and is headquartered in Rockville, MD.

apceth Biopharma GmbH operates as a contract development & manufacturing organization. The firm specializes in cell-based and gene therapy products (Advanced Therapy Medicinal Products, ATMPs). Its GMP services include quality management, quality control, assay development, process development, cell banking & formulation and project management. The company was founded in 2007 and is headquartered in Munich, Germany.

Part of Sanofi, Kiadis Pharma Canada, Inc. manufactures and supplies pharmaceutical products. The company is based in Saint-Laurent, Canada.

Kiadis Pharma Deutschland GmbH develops drugs for blood cancer. The private company is based in Munich, Germany.

Charité Research Organisation GmbH is a contract research organization that helps clients move development projects from first time in human to proof of concept as quickly and efficiently as possible. The private company is based in Berlin, Germany and was founded in 2005 by Frank Wagner, who has been the CEO since then. Charité Research Organisation offers scientific and regulatory consultancy, protocol development, routine laboratory, biomarker laboratory, imaging, project management, monitoring, data management, biostatistics, and medical writing services. The German company also provides world-leading patient and healthy volunteer recruitment capabilities and delivers the best value solution for early clinical development.

CatalYm GmbH specializes in catalyzing immunotherapy. The company is headquartered in Munich, Germany.

3B Pharmaceuticals GmbH is a German biotechnology company that specializes in developing targeted radiopharmaceutical drugs and diagnostics for oncology indications with a high unmet medical need. The company is based in Germany. The private company is a leader in peptide discovery and optimization, with a technology platform that extends from hit identification to early clinical development. The company is owned by its founders and management. 3BP was founded in 2008 by a team of renowned experts in peptide drug discovery and nuclear medicine from Bern and Basel. The company was founded in 2008 by Jochen Knolle. The CEO is Ulrich Reineke.

Part of Affimed NV, Affimed GmbH is a clinical leader in innate immuno-oncology. The company, based in Heidelberg, Germany, develops proprietary cancer-targeting bispecific antibodies that activate the innate immune system to kill tumor cells. Affimed leads clinical development of innate cell engagers for solid/hematologic tumors as monotherapy, in combination with NK cells or with checkpoint inhibitors. Adolf Hoess has been the CEO of the German company since 2010.

Pharvaris GmbH operates as a clinical-stage company. It specializes in medicinal chemistry, drug discovery and development and hereditary angioedema. The company was founded by Berndt A. E. Modig, Jochen Knolle, Anne Lesage and Hans G. C. P. Schikan in October 2015 and is headquartered in Zug, Switzerland.

HeartBeat.bio AG is an Austrian company that specializes in developing a high-throughput human organoid screening platform for cardiac drug discovery. HeartBeat.bio is based in Vienna, AT, at the Biocenter. The company's technology platform is based on self-organizing, scalable cardiac organoids that replicate human heart physiology, allowing for modeling of various diseases such as drug-induced and genetic cardiomyopathies, myocardial infarction, heart remodeling, and regeneration. The company was founded in 2021 by a team with extensive experience in organoid research, drug discovery, and business development. Michael Krebs has been the CEO since incorporation.

Ariceum Therapeutics GmbH is a German clinical stage radiopharmaceutical company that focuses on the diagnosis and precision treatment of certain neuroendocrine and other aggressive, hard-to-treat cancers. Ariceum Therapeutics is based in Berlin, DE, and has subsidiaries in various locations worldwide. The company's lead targeted systemic radiopharmaceutical product, -satoreotide tetraxetan ("satoreotide"), is an antagonist of the somatostatin type 2 (sstr2) receptor, which is overexpressed in neuroendocrine tumors (NETs) and some aggressive cancers such as small cell lung cancer (SCLC) and Merkel cell carcinoma. Ariceum is also developing a radiolabeled PARP-inhibitor (ATT-001), which is slated to enter the clinic in early 2024. The company was founded in 2021, and Manfred Rüdiger has been the CEO of the company since 2021.

High-Tech Gründerfonds Management GmbH (HTGF) is a venture capital firm founded in 2005. The firm is headquartered in Bonn, Germany.